stockrow
Friday 6 November 2026
Export ATYR’s income statement to Excel — free account
aTyr Pharma, Inc.
ATYR Healthcare Biotechnology
aTyr Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $190,000.00, down 19.1% from fiscal 2024.
- Revenue
- −90.8%
- EPS
- +51.5%
- Free cash flow
- +32.2%
- Total debt
- −94.0%
Quarter to June 2026, against a year earlier
6.28
0.25
+4.15%
Follow ATYR
Alert me
aTyr Pharma, Inc. (ATYR) P/E ratio
aTyr Pharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2025 | 0.0× | — |
| Mar 2024 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| Dec 2022 | 0.0× | — |
| 7 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NEUP Neuphoria Therapeutics Inc. compare | n/m |
| PLUR Pluri Inc. compare | n/m |
| MRKR MARKER THERAPEUTICS, INC. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | n/m |
| ATYR aTyr Pharma, Inc. | n/m |
| VAXX Vaxxinity, Inc. compare | n/m |
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| ABOS Acumen Pharmaceuticals, Inc. compare | n/m |
| KYNB Kyntra Bio Inc compare | 0.1× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)